Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139)

R. P. Kadota, L. R. Mandell, J. Fontanesi, E. H. Kovnar, J. Krischer, L. E. Kun, H. S. Friedman

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

A phase I Pediatric Oncology Group Study was performed combining 7, 020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalPediatric Neurosurgery
Volume20
Issue number4
DOIs
StatePublished - Jan 1 1994

    Fingerprint

Keywords

  • Brain neoplasms
  • Brain stem
  • Cisplatin
  • Radiotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Clinical Neurology

Cite this

Kadota, R. P., Mandell, L. R., Fontanesi, J., Kovnar, E. H., Krischer, J., Kun, L. E., & Friedman, H. S. (1994). Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139). Pediatric Neurosurgery, 20(4), 221-225. https://doi.org/10.1159/000120794